Bharat Biotech’s Covid-19 nasal vaccine Incovacc has received the government’s approval for use as a booster dose on Dec 23
Bharat Biotech's intranasal Covid vaccine will be available in private centres and will be introduced on CoWIN on Dec 23, as per an India Today report
Incovacc received a go ahead from the Central Drugs Standard Control Organisation for restricted use in emergency situations for people aged 18 and above few weeks ago
The government in its press release called Incovacc the ‘World’s first intra-nasal vaccine for Covid’. Here’s everything to know about the nasal vaccine
The nasal vaccine is administered through the nose, as a 2-dose series, four weeks apart. A total of 8 drops (0.5 ml per dose), 4 drops are administered into each nostril
The delivery process is non-invasive and needle-free. Thus, avoiding needle-associated risks like injuries and infections
Due to the simple-delivery process, Bharat Biotech’s new nasal vaccine does not require trained health-care workers to administer the booster dose
As per Bharat Biotech, reported side-effects observed during clinical trials include headache, fever, running nose and sneezing. However, severe side effects are rare
Bharat Biotech advises against receiving a dose for individuals who:
-Have a severe allergic reaction to any ingredients of the vaccine
-Had a severe allergic reaction after a previous dose of this vaccine
-Currently have an acute infection or fever
Produced By: Anshula Raj
Designed By: Mohsin